

Genomic and Molecular Biomarker Testing for Cancer



Medicaid Medical Coverage Policy

Original Effective Date: 08/05/2025

Effective Date: 12/03/2025

Review Date: 08/05/2025

Policy Number: HUM-2248-000

Line of Business: Medicaid

States: Virginia

Table of Contents

[Description](#)

[Coverage Limitations](#)

[References](#)

[Appendix](#)

[Coverage Determination](#)

[Coding Information](#)

[Change Summary](#)

Disclaimer

The Medical Coverage Policies are reviewed by the Humana Medicaid Coverage Policy Adoption (MCPA) Forum. Policies in this document may be modified by a member's coverage document. Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. References to CPT® codes or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee of claims payment. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

Table of Contents

Category	Tests
Concurrent (Paired) DNA and RNA Genetic Testing	• +RNAinsight for APC • +RNAinsight for MSH2 • +RNAinsight for MSH6 • +RNAinsight for PMS2 • +RNAinsight for Lynch Syndrome • +RNAinsight for ProstateNext
Hematologic Malignancies and Suspected Myeloid Disorders - Comprehensive Genomic Profiling/Multigene Panel Testing	• Augusta Hematology Optical Genome Mapping • DH Optical Genome Mapping/Digital Karyotyping Assay • MyAML NGS Panel
Hematologic Malignancies and Suspected Myeloid Disorders – Single Gene Testing	• ASXL1 • BTK • CCND1 • CEBPA • EZH2 • IDH1/IDH2 • MYD88

	• <i>NPM1</i> • <i>PLCG2</i> • <i>RUNX1</i> • <i>SF3B1</i> • <i>SRSF2</i> • <i>U2AF1</i> • <i>ZRSR2</i>
Liquid Biopsy	• Avantect Pancreatic Cancer Test • BTG Early Detection of Pancreatic Cancer • Colon AIQ • ColoScape • Colvera • DefineMBC • FoundationOne Liquid CDx • HelioLiver • InVisionFirst-Lung • Liquid HALLMARK • LungLB • miR Sentinel Prostate Cancer Test • RadTox • Resolution ctDx Lung • Select MDx
Minimal Residual Disease	• ClonoSEQ MRD Detection • Genomic Health OncoDetect • Guardant Reveal • Guardant360 Response • HPV-SEQ • Invitae PCM MRD Monitoring • Invitae PCM Tissue Profiling and MRD Baseline Assay • MyMRD • NavDx • Signatera • UroAmp MRD
Molecular Markers in Fine Needle Aspirates of Thyroid Nodules	• Afirma XA • Thyroid GuidePx • ThyroSeq CRC
Multianalyte Assays with Algorithmic Analyses	• EpiSwitch Prostate Screening Test • Lung OI • NETest • Nodify CDT • OVA1 • ROMA

	• Veristrat
Solid Tumors - Comprehensive Genomic Profiling	• Chromosomal microarray • Comprehensive genomic profiling • ExaCT-1 Whole Exome Testing • Guardant360 Tissue Next • MI Cancer Seek • MSK-IMPACT • MyChoice CDx • Oncomap ExTra • Oncomine Dx Target Test • Oncotype MAP PanCancer Tissue Test • PGDx elio tissue complete • Praxis Somatic Combined Whole Genome Sequencing and Optical Genome Mapping • Praxis Somatic Optical Genome Mapping Test • Praxis Somatic Transcriptome • Praxis Somatic Whole Genome Sequencing Test
Solid Tumors – Single Gene Testing	• <i>IDH1</i> • <i>IDH2</i> • <i>MGMT</i> • <i>PIK3CA</i> • <i>TERT</i> • therascreen FGFR RGQ RT-PCR Kit • therascreen PIK3CA RGQ PCR Kit
Tumor Markers	• Des-gamma-carboxy prothrombin • Human epididymis protein 4 (HE4) • IsoPSA

Concurrent (Paired) DNA and RNA Genetic Testing

Description

Concurrent (paired) DNA and RNA genetic testing (also referred to as expanded RNA analysis) is a type of multigene panel test that analyzes DNA in combination with RNA purported to aid with the detection, diagnosis and management of cancer as well as classification of variants of unknown significance (VUS). Paired testing may be offered to an individual who is at increased risk for hereditary cancer, such as colorectal and prostate cancer, and is performed concurrent to DNA testing to identify additional variants (mutations). **+RNAinsight** is an example of paired genetic testing and is conducted as an add-on test for multigene hereditary colorectal cancer panels such as **Lynch syndrome**. +RNAinsight has also been proposed for use with single gene testing for colorectal cancer (eg, *APC*, *MLH1*, *MSH2*, *MSH6* and *PMS2*). **+RNAinsight for ProstateNext** has been proposed for individuals diagnosed with prostate cancer.

Coverage Determination

There are no covered indications; refer to Coverage Limitations Section.

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for any of the following tests:

- Concurrent (paired) DNA/RNA genetic testing:
 - +RNAinsight for APC (0157U)
 - +RNAinsight for MSH2 (0159U)
 - +RNAinsight for MSH6 (0160U)
 - +RNAinsight for PMS2 (0161U)
 - +RNAinsight for Lynch Syndrome (0162U)
 - +RNAinsight for ProstateNext (0133U)

A review of the current medical literature shows that the **evidence is insufficient** to determine that this service is standard medical treatment. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of this service in clinical management.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
0133U	Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure)	
0157U	APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)	
0159U	MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	
0160U	MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	

0161U	PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	
0162U	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure)	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. Horton C, Hoang L, Zimmerman H, et al. Diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary cancer testing. *JAMA Oncol*. 2023:e235586.
2. Karam R, Conner B, LaDuca H, et al. Assessment of diagnostic outcomes of RNA genetic testing for hereditary cancer. *JAMA Netw Open*. 2019; 2(10):e1913900.
3. Landrith T, Li B, Cass AA, et al. Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes. *NPI Precis Oncol*. 2020;4:4.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast, ovarian, pancreatic, and prostate. <https://nccn.org>. Updated March 6, 2025.
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: colorectal, endometrial, and gastric. <https://nccn.org>. Updated June 13, 2025.
6. UpToDate, Inc. Lynch syndrome (hereditary nonpolyposis colorectal cancer): clinical manifestations and diagnosis. <https://uptodate.com>. Updated May 29, 2025.

Description

Comprehensive genomic profiling (CGP) (also referred to as comprehensive molecular profiling) is a type of test that involves a combination of laboratory methodologies to detect genetic alterations and biomarkers in blood or bone marrow to aid in the management of hematologic malignancies and suspected myeloid disorders. Testing is performed by removing a small sample of tissue for evaluation (eg, bone marrow biopsies, bone marrow aspirates, bone marrow clots), blood draw (peripheral blood samples), or sites located outside of the bone marrow (extramedullary) suspected of harboring a myeloid malignancy. Techniques can vary from test to test and may include but are not limited to, next-generation sequencing (NGS), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Examples of CGP tests include, but are not limited to, **FoundationOne Heme and Neogenomics myeloid and/or heme panels**.

Multigene (or expanded) panels analyze a broad set of genes simultaneously (as opposed to single gene testing that searches for variants in one specific gene). Panels often include medically actionable genes but may also include those with unclear medical management. Targeted (or focused) multigene panels analyze a limited number of genes targeted to a specific condition. An example of a multigene panel includes, but may not be limited to, **MyAML Gene Panel Assay**.

Optical genome mapping (OGM) is a laboratory technique used to analyze long stretches of DNA allowing a broad view of the genome to detect large structural variations. This type of test may be able to detect changes that other assays may miss such as deletions, duplications, insertions, inversions and translocations. OGM has been proposed for use in hematologic malignancies and include tests such as **Augusta Hematology Optical Genome Mapping** and **DH Optical Genome Mapping/Digital Karyotyping Assay**.

Coverage Determination

Comprehensive Genomic Profiling or Multigene Panel Testing for Hematologic Malignancies and Suspected Myeloid Disorders

Humana members may be eligible under the Plan for **comprehensive genomic profiling or multigene panel testing (81450, 81451, 81455, 81456)** for any of the following indications:

- Cancer of the blood and bone marrow (eg, acute myelogenous leukemia [AML])¹⁴; **OR**
- Myelodysplastic syndrome (MDS)¹⁵; **OR**
- Myeloproliferative neoplasms (MPNs) which include polycythemia vera (PV), essential thrombocythemia (ET) or primary myelofibrosis (PMF)¹⁶; **OR**
- Suspected myeloid malignancy (does not have a diagnosis of cancer) with [undefined cytopenia](#)* for greater than four months without a known cause¹³; **OR**
- Systemic mastocytosis¹⁸

MyAML Gene Panel Assay

Humana members may be eligible under the Plan for **MyAML Gene Panel Assay (0050U)** for the management of acute myeloid leukemia (AML)¹⁴.

*Clinical, laboratory and pathologic assessment are nondiagnostic (such as demonstration of persistent cytopenias [eg, four months] by complete blood count, microscopic examination of a bone marrow biopsy and bone marrow cytogenetic studies. Other than the clinical feature of the number of cytopenias and specific cytogenetic changes found recurrently in myelodysplastic syndrome [MDS], all other diagnostic criteria in MDS rely upon light microscopy findings).¹³

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for **optical genome mapping** including, but not limited to:

- Augusta Hematology Optical Genome Mapping (0331U)
- DH Optical Genome Mapping/Digital Karyotyping Assay (0413U)

A review of the current medical literature shows that there is **no evidence** to determine that these services are standard medical treatments. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of these services in clinical management.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81450	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA	
81451	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	

81455	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA an	
81456	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA an	
0050U	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements	
0331U	Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alterations	
0413U	Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228.
2. Association for Molecular Pathology (AMP). Clinical significance of DNA variants in chronic myeloid neoplasms: a report of the Association for Molecular Pathology. <https://amp.org>. Published November 2018.

3. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer J*. 2018; 8(2):15.
4. ClinicalKey. Clinical Overview. Acute myelogenous leukemia. <https://clinicalkey.com>. Updated March 10, 2025.
5. ClinicalKey. Clinical Overview. Myelodysplastic syndrome. <https://clinicalkey.com>. Updated January 1, 2025.
6. College of American Pathologists (CAP). CAP Laboratory Improvement Programs. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. <https://cap.org>. Published October 2017.
7. ECRI Institute. ECRIgene. NeoTYPE AML Prognostic Profile (NeoGenomics Laboratories Inc.) for prognosis of acute myeloid leukemia. <https://home.ecri.org>. Published March 2019.
8. ECRI Institute. ECRIgene Genetic Test Product Brief. FoundationOne Heme (Foundation Medicine, Inc.) genomic profiling test for guiding therapy for blood cancers and sarcomas. <https://home.ecri.org>. Published January 2020.
9. Hayes, Inc. Clinical Utility Evaluation. Genetic testing for the diagnosis and treatment of polycythemia vera (PV). <https://evidence.hayesinc.com>. Published April 2, 2018. Updated June 17, 2022.
10. Hayes, Inc. Clinical Utility Evaluation. Genetic testing for the diagnosis and treatment monitoring of primary myelofibrosis (PMF). <https://evidence.hayesinc.com>. Published April 12, 2018. Updated June 17, 2022.
11. Hayes, Inc. GTE Report. Molecular/cytogenetic testing for diagnosis and prognosis in primary/de novo acute myeloid leukemia (AML). <https://evidence.hayesinc.com>. Published July 24, 2014. Updated July 7, 2015.
12. Hayes, Inc. Molecular Test Assessment. FoundationOne Heme (Foundation Medicine Inc.). <https://evidence.hayesinc.com>. Published August 18, 2023. Updated September 17, 2024.
13. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *Leukemia*. 2022;36(7):1703-1719.
14. Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. *Blood*. 2017;129(25):3371-3378.
15. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. <https://nccn.org>. Updated January 27, 2025.

16. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. <https://nccn.org>. Updated January 17, 2025.
17. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Myeloproliferative neoplasms. <https://nccn.org>. Updated February 21, 2025.
18. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Systemic mastocytosis. <https://nccn.org>. Updated February 21, 2025.
19. UpToDate, Inc. Acute myeloid leukemia: clinical manifestations, pathologic features, and diagnosis. <https://uptodate.com>. Updated May 2025.
20. UpToDate, Inc. Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS). <https://uptodate.com>. Updated May 2025.
21. UpToDate, Inc. General aspects of cytogenetic analysis in hematologic malignancies. <https://uptodate.com>. Updated May 2025.
22. Yu J, Li Y, Li T, et al. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. *Exp Hematol Oncol*. 2020;9:2.
23. Zheng G, Chen P, Pallavajjala A, et al. The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia. *Am J Hematol*. 2019;94(10):1141-1148.

HEMATOLOGIC MALIGNANCIES AND SUSPECTED MYELOID DISORDERS

Single Gene Testing

Description

Single gene testing may also be performed for hematologic malignancies and suspected myeloid disorders and may be indicated for an individual who exhibits disease symptoms and may be necessary to diagnose or rule out suspected cancer or monitor known cancer. These include, but are not limited to, *ASXL1*, *BTB*, *CCND1*, *CEBPA*, *EZH2*, *IDH1*, *IDH2*, *MYD88*, *NPM1*, *PLCG2*, *RUNX1*, *SF3B1*, *SRSF2*, *U2AF1*, and *ZRSR2*.

Coverage Determination

ASXL1 Gene Testing

Humana members may be eligible under the Plan for **ASXL1 gene testing (81175/81176)** for any of the following indications:

- AML (includes acute promyelocytic leukemia [APL]); **OR**
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN); **OR**
- Chronic myeloid leukemia (CML) ¹⁵; **OR**
- Myelodysplastic syndrome (MDS); **OR**

- Myeloproliferative neoplasms (MPN); **OR**
- Suspected myeloid malignancy with [undefined cytopenia](#)*; **OR**
- Systemic mastocytosis

BTK Gene Testing

Humana members may be eligible under the Plan for **BTK gene testing (81233)** for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in an individual with disease progression or no response while taking BTK inhibitor therapy including if poor adherence is considered as a possible cause.

CCND1::IGH t(11;14) Translocation Testing

Humana members may be eligible under the Plan for **CCND1::IGH t(11;14) translocation testing (81168)** for any of the following indications:

- Chronic lymphocytic leukemia/small lymphocytic lymphoma; **OR**
- Diffuse large B-cell lymphoma⁵; **OR**
- Extranodal marginal zone B-cell lymphoma of nongastric sites (noncutaneous); **OR**
- Extranodal marginal zone B-cell lymphoma of the stomach; **OR**
- Follicular lymphoma; **OR**
- Lymphoblastic lymphoma; **OR**
- Mantle cell lymphoma; **OR**
- Nodal marginal zone lymphoma; **OR**
- Splenic marginal zone lymphoma

CEBPA Gene Testing

Humana members may be eligible under the Plan for **CEBPA gene testing (81218/81219)** for any of the following indications:

- AML (includes APL); **OR**
- MDS; **OR**
- Suspected myeloid malignancy with [undefined cytopenia](#)*

EZH2 Gene Testing

Humana members may be eligible under the Plan for **EZH2 gene testing (81236/81237)** for any of the following indications:

- AML (includes APL); **OR**
- Diffuse large b-cell lymphoma; **OR**
- Follicular lymphoma to determine benefit of treatment with tazemetostat (Tazverik) performed with an FDA-approved test; **OR**

- MDS; **OR**
- MPNs

IDH1/IDH2 Gene Testing

Humana members may be eligible under the Plan for **IDH1 (81120) and/or IDH2 (81121) gene testing** for any of the following indications:

- AML (includes APL); **OR**
- CML; **OR**
- MDS; **OR**
- MPN; **OR**
- Suspected myeloid malignancy with [undefined cytopenia](#)*

MYD88 Gene Testing

Humana members may be eligible under the Plan for **MYD88 gene testing (81305)** for any of the following indications:

- Extranodal marginal zone B-cell lymphoma of nongastric sites (noncutaneous); **OR**
- Extranodal marginal zone B-cell lymphoma of the stomach; **OR**
- Monoclonal gammopathy of neurological significance (MGNS); **OR**
- Monoclonal gammopathy of renal significance (MGRS); **OR**
- Multiple myeloma; **OR**
- Nodal marginal zone lymphoma; **OR**
- Splenic marginal zone lymphoma; **OR**
- Systemic light chain amyloidosis if lymphoplasmacytic clone is present; **OR**
- Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma

NPM1 Gene Testing

Humana members may be eligible under the Plan for **NPM1 gene testing (81310/0049U)** for any of the following indications:

- AML (includes APL); **OR**
- MDS; **OR**
- Suspected myeloid malignancy with [undefined cytopenia](#)*

PLCG2 Gene Testing

Humana members may be eligible under the Plan for **PLCG2 gene testing (81233)** for chronic lymphocytic leukemia/small lymphocytic lymphoma in an individual with disease progression or no response while taking BTK inhibitor therapy including if poor adherence is considered as a possible cause.

RUNX1 Gene Testing

Humana members may be eligible under the Plan for **RUNX1 gene testing (81334)** for any of the following indications:

- ALL; **OR**
- AML (includes APL); **OR**
- MDS; **OR**
- Suspected myeloid malignancy with [undefined cytopenia](#)*; **OR**
- Systemic mastocytosis

SF3B1 Gene Testing

Humana members may be eligible under the Plan for **SF3B1 gene testing (81347)** for any of the following indications:

- CML; **OR**
- MDS; **OR**
- Suspected myeloid malignancy with [undefined cytopenia](#)*; **OR**
- Symptomatic anemia

SRSF2 Gene Testing

Humana members may be eligible under the Plan for **SRSF2 gene testing (81348)** for any of the following indications:

- AML (includes APL); **OR**
- MDS; **OR**
- MPN; **OR**
- Suspected myeloid malignancy with [undefined cytopenia](#)*; **OR**
- Systemic mastocytosis

U2AF1 Gene Testing

Humana members may be eligible under the Plan for **U2AF1 gene testing (81357)** for any of the following indications:

- AML (includes APL); **OR**
- MDS; **OR**
- MPN; **OR**
- Suspected myeloid malignancy with [undefined cytopenia](#)*

ZRSR2 Gene Testing

Humana members may be eligible under the Plan for **ZRSR2 gene testing (81360)** for any of the following indications:

- AML (includes APL); **OR**
- MDS; **OR**
- Suspected myeloid malignancy with [undefined cytopenia](#)*

*Clinical, laboratory and pathologic assessment are nondiagnostic (such as demonstration of persistent cytopenias [eg, four months] by complete blood count, microscopic examination of a bone marrow biopsy and bone marrow cytogenetic studies. Other than the clinical feature of the number of cytopenias and specific cytogenetic changes found recurrently in myelodysplastic syndrome [MDS], all other diagnostic criteria in MDS rely upon light microscopy findings).

Coverage Limitations

There are no limitations; refer to Coverage Determination Section.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81120	IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common variants (eg, R132H, R132C)	
81121	IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (eg, glioma), common variants (eg, R140W, R172M)	
81168	CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed	
81175	ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence	
81176	ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted sequence analysis (eg, exon 12)	
81218	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence	

81233	BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)	
81236	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence	
81237	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)	
81305	MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant	
81310	NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants	
81320	PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)	
81334	RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy), gene analysis, targeted sequence analysis (eg, exons 3-8)	
81347	SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L)	
81348	SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L)	
81357	U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P)	
81360	ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (eg, E65fs, E122fs, R448fs)	
0049U	NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *Leukemia*. 2022;36(7):1703-1719.
2. National Comprehensive Cancer Network (NCCN). NCCN Biomarkers Compendium. ASXL1, BTK, CCND1 t(11;14), CEBPA, EZH2, IDH1, IDH2, MYD88, NPM1, PLCG2, RUNX1, SF3B1, SRSF2, U2AF1, ZRSR2. <https://nccn.org>. Updated 2025.
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Acute lymphoblastic leukemia. <https://nccn.org>. Updated June 27, 2025.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. <https://nccn.org>. Updated January 27, 2025.
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. B-cell lymphomas. <https://nccn.org>. Updated February 10, 2025.
6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma. <https://nccn.org>. Updated April 2, 2025.
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Chronic myeloid leukemia. <https://nccn.org>. Updated November 27, 2024.
8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Multiple myeloma. <https://nccn.org>. Updated June 24, 2025.
9. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. <https://nccn.org>. Updated January 17, 2025.
10. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Myeloproliferative neoplasms. <https://nccn.org>. Updated February 21, 2025.
11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Systemic light chain amyloidosis. <https://nccn.org>. Updated June 11, 2025.
12. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Systemic mastocytosis. <https://nccn.org>. Updated February 21, 2025.
13. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. <https://nccn.org>. Updated June 24, 2025.

14. US Food & Drug Administration (FDA). Full prescribing information: Tazverik (tazemetostat). <https://fda.gov>. Published 2020. Updated August 2024.
 15. US Food & Drug Administration (FDA). List of cleared or approved companion diagnostic devices (in vitro and imaging tools). <https://fda.gov>. Updated March 5, 2025.
 16. US Food & Drug Administration (FDA). Premarket approval. cobas EZH2 Mutation Test. <https://fda.gov>. Published June 22, 2020.
-

Liquid Biopsy

Description

Liquid biopsy is a minimally invasive laboratory technique that detects cancer-related genetic material, such as circulating tumor DNA (ctDNA) or cell-free DNA (cfDNA), in a blood sample or other body fluids. Unlike traditional tissue biopsies, liquid biopsies can provide a snapshot of tumor activity throughout the body, allowing for earlier detection, real-time monitoring of disease progression and assessment of treatment response. Examples of ctDNA tests include, but are not limited to, **FoundationOne Liquid CDx**, **Guardant360 CDx** and **LiquidHALLMARK**. Examples of cfDNA tests include, but are not limited to, **RadTox**.

ColonAiQ examines faint tumor signals circulating in an individual's blood that are specific to colon cancer and the precursor polyps of the disease called advanced adenoma. The test uses patented DNA methylation technology that can find small traces of tumor cell-free DNA (cfDNA) in the blood even at incredibly small concentrations.

Colvera is a blood test for the monitoring of colorectal cancer for post-surgical recurrence.

HelioLiver is a blood-based test that combines ctDNA markers and protein biomarkers, analyzed through machine learning to aid in the detection of hepatocellular carcinoma (HCC). The test is intended for use in those at risk for HCC, such as individuals with chronic liver disease or cirrhosis.

LungLB is a laboratory blood-based fluorescence in situ hybridization (FISH) assay for the evaluation of indeterminate pulmonary nodules purposed for the early detection of lung cancer.

Resolution ctDX Lung has been proposed for use in genotyping lung cancer tumors to help determine appropriate treatment options.

SelectMDx is a noninvasive urine-based molecular test that measures the mRNA expression levels of prostate cancer-related genes. It is used to help stratify the risk of high-grade prostate cancer in those with elevated prostate specific antigen (PSA) levels, supporting decisions about proceeding with prostate biopsy.

Coverage Determination

Humana members may be eligible under the Plan for **FoundationOne Liquid CDx (0239U)** when the following criteria are met:

- Individual diagnosed with recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer;
AND
- Tissue-based, comprehensive genomic profiling (CGP) is infeasible (eg, quantity not sufficient for tissue-based CGP or [invasive biopsy is medically contraindicated](#)[^]) or specifically in non-small cell lung cancer (NSCLC) tissue-based CGP has shown no actionable mutations
- Individual has decided to seek further cancer treatment (eg, therapeutic chemotherapy)

[^]Invasive biopsy may be medically contraindicated when the procedure poses significant risk, such as when the only available biopsy site is bone, precarious performance status, significant delay is expected in obtaining tumor tissue for genotyping, when lesions are small or diffuse or when the biopsy site is located in an area that is difficult to access without substantial risk of morbidity.

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for the following liquid biopsy tests:

- Avantect Pancreatic Cancer Test (0410U)
- BTG Early Detection of Pancreatic Cancer (0405U)
- Colon AIQ (0453U)
- ColoScape (0368U)
- Colvera (0229U)
- HelioLiver (0333U)
- InVisionFirst-Lung (0388U)
- Liquid HALLMARK (0409U)
- LungLB (0317U)
- miR Sentinel Prostate Cancer Test (0424U)
- RadTox (0285U)
- Resolution ctDx Lung (0179U)
- Select MDx (0339U)

A review of the current medical literature shows that the **evidence is insufficient** to determine that this service is standard medical treatment. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of this service in clinical management.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81462	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements	
81463	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability	
81464	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements	
0011M	Oncology, prostate cancer, mRNA expression assay of 12 genes (10 content and 2 housekeeping), RT-PCR test utilizing blood plasma and urine, algorithms to predict high-grade prostate cancer risk	
0179U	Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)	
0229U	BCAT1 (Branched chain amino acid transaminase 1) and IKZF1 (IKAROS family zinc finger 1) (eg, colorectal cancer) promoter methylation analysis	
0239U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free DNA, analysis of 311 or more genes, interrogation for sequence variants, including substitutions, insertions, deletions, select rearrangements, and copy number variations	
0285U	Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score	
0317U	Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm generated evaluation reported as decreased or increased risk for lung cancer	

0326U	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	
0333U	Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP), algorithm reported as normal or abnormal result	
0339U	Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer	
0368U	Oncology (colorectal cancer), evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132 and TWIST1), multiplex quantitative polymerase chain reaction (qPCR), circulating cell-free DNA (cfDNA), plasma, report of risk score for advanced adenoma or colorectal cancer	
0388U	Oncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection	
0405U	Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected	
0409U	Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, report showing identified mutations with clinical actionability	
0410U	Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected	
0424U	Oncology (prostate), exosome-based analysis of 53 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer	

0453U	Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation-based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. Agency for Healthcare Research and Quality (AHRQ). Role of liquid biopsy in detection and management of cancer in the Medicare population. <https://www.ahrq.gov>. Published January 22, 2021. Updated July 29, 2021.
2. American Association for the Study of Liver Diseases (AASLD). AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. <https://www.aasld.org>. Published December 2023.
3. American Society of Clinical Oncology (ASCO). Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. <https://asco.org>. Published February 17, 2022.
4. American Society of Colon and Rectal Surgeons (ASCRS). Management of colon cancer. <https://fascrs.org>. Published February 2022.
5. Association for Molecular Pathology (AMP). Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? <https://amp.org>. Published May 2015.
6. Association for Molecular Pathology (AMP). Molecular biomarkers for the evaluation of colorectal carcinoma: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <https://amp.org>. Published February 6, 2017.
7. Association for Molecular Pathology (AMP). Recommendations for cell-free DNA assay validations. A joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. <https://amp.org>. Published October 6, 2023.
8. Association for Molecular Pathology (AMP). Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <https://amp.org>. Published March 2018.

9. ECRI Institute. ECRIGene. FoundationOne Liquid (Foundation Medicine, Inc.) genomic profiling and liquid biopsy test for guiding targeted therapy for solid tumors. <https://home.ecri.org>. Published September 2019.
10. ECRI Institute. ECRIGene Genetic Test Assessment. Avantect Pancreatic Cancer Test (ClearNote Health) for pancreatic cancer screening. <https://home.ecri.org>. Published July 2024.
11. ECRI Institute. ECRIGene Genetic Test Assessment. Colvera (Clinical Genomics Pathology, Inc.) liquid biopsy test to monitor for recurrent colorectal cancer. <https://home.ecri.org>. Published October 21, 2021.
12. ECRI Institute. ECRIGene Genetic Test Assessment. Guardant360 CDx Test (Guardant Health, Inc.) for informing management of advanced solid tumor cancers. <https://home.ecri.org>. Published September 2024.
13. ECRI Institute. ECRIGene Genetic Test Assessment. HelioLiver Test (Fulgent Genetics) for aiding diagnosis of liver cancer. <https://home.ecri.org>. Published May 2023.
14. ECRI Institute. ECRIGene Genetic Test Assessment. InVisionFirst-Lung (Inivata Ltd) genomic profiling and liquid biopsy test for guiding targeted therapy for non-small cell lung cancer. <https://home.ecri.org>. Published June 2021.
15. ECRI Institute. ECRIGene Genetic Test Assessment. miR Sentinel Prostate Cancer Test (miR Scientific) for assessing risk of aggressive prostate cancer. <https://home.ecri.org>. Published March 2023.
16. Hayes, Inc. Molecular Test Assessment. Colvera (Clinical Genomics Pathology Inc.). <https://evidence.hayesinc.com>. Published November 14, 2018. Updated July 1, 2022.
17. Hayes, Inc. Molecular Test Assessment. FoundationOne Liquid (Foundation Medicine Inc.). <https://evidence.hayesinc.com>. Published June 13, 2019.
18. Hayes, Inc. Molecular Test Assessment. FoundationOne Liquid CDx (Foundation Medicine Inc.). <https://evidence.hayesinc.com>. Published November 30, 2023. Updated November 22, 2024.
19. Hayes, Inc. Molecular Test Assessment. Guardant360 and Guardant360 CDx (Guardant Health Inc.). <https://evidence.hayesinc.com>. Published August 1, 2024.
20. Hayes, Inc. Precision Medicine Research Brief. Comprehensive molecular profiling of circulating solid tumor DNA for the intended use as a broad molecular profiling tool for monitoring. <https://evidence.hayesinc.com>. Published October 18, 2022.
21. Hayes, Inc. Precision Medicine Research Brief. Comprehensive molecular profiling of circulating solid tumor DNA for the intended use as a broad molecular profiling tool to aid treatment selection. <https://evidence.hayesinc.com>. Published October 18, 2022.

22. Hayes, Inc. Precision Medicine Research Brief. RadTox cfDNA Test (DiaCarta Inc.). <https://evidence.hayesinc.com>. Published December 7, 2022.
23. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer. <https://nccn.org>. Updated April 17, 2025.
24. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon cancer. <https://nccn.org>. Updated June 27, 2025.
25. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma. <https://nccn.org>. Updated February 3, 2025.
26. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Rectal cancer. <https://nccn.org>. Updated March 31, 2025.
27. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. <https://nccn.org>. Updated July 10, 2025.
28. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. <https://nccn.org>. Updated April 16, 2025.
29. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. <https://www.sitcancer.org>. Published 2023.
30. UpToDate, Inc. Adjuvant therapy for resected stage II colon cancer. <https://uptodate.com>. Updated July 10, 2025.
31. UpToDate, Inc. Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer. <https://uptodate.com>. Updated June 2025.
32. UpToDate, Inc. General principles of systemic therapy for metastatic colorectal cancer. <https://uptodate.com>. Updated June 2025.
33. UpToDate, Inc. Personalized, genotype-directed therapy for advanced non-small cell lung cancer. <https://uptodate.com>. Updated June 4, 2025.
34. UpToDate, Inc. Post-treatment surveillance for colorectal cancer. <https://uptodate.com>. Updated July 16, 2025.
35. US Food & Drug Administration (FDA). Premarket Approval (PMA). FoundationOne Liquid CDx. <https://fda.gov>. Published September 1, 2020. Updated November 14, 2024.
36. US Food & Drug Administration (FDA). Premarket Approval (PMA). Guardant360 CDx. <https://fda.gov>. Published August 28, 2020. Updated January 27, 2023.

37. US Food & Drug Administration (FDA). Premarket Approval (PMA). Agilent Resolution CtDx FIRST. <https://fda.gov>. Published December 12, 2022.

Minimal Residual Disease

Description

Minimal residual disease (MRD) testing for cancer measures the amount of cancer cells circulating in the blood of an individual with cancer. Although it is a relatively new application of novel genomic technologies, MRD testing has demonstrated its ability to impact cancer diagnosis and treatment thus enabling providers to better assign risk stratification, deploy alternate treatment strategies, or reduce the use of unnecessary adjuvant therapies. Certain MRD tests can be used to monitor the response to immune checkpoint inhibitor (ICI) therapy for individuals with solid tumors. Examples of MRD testing in hematologic malignancies include, but are not limited to, **ClonoSEQ** and **MyMRD**. Examples of MRD testing for solid tumors include, but are not limited to, **Guardant360Response**, **NavDx** and **Signatera**.

Coverage Determination

HEMATOLOGIC MALIGNANCIES

Humana members may be eligible under the Plan for the assessment of **minimal residual disease (MRD) for hematologic malignancies** using the following test:

- MyMRD Gene Panel Assay (0171U) for acute myeloid leukemia (AML)

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for any of the following MRD tests:

- Genomic Health OncoDetect (81479)
- Guardant Reveal (0569U)
- HPV-SEQ (0470U)
- Invitae PCM MRD Monitoring (0307U)
- Invitae PCM Tissue Profiling & MRD Baseline Assay (0306U)
- NavDx (0356U)
- Signatera (0340U)
- UroAmp MRD (0467U)

A review of the current medical literature shows that the **evidence is insufficient** to determine that this service is standard medical treatment. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of this service in clinical management.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
0171U	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence	
0306U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient-specific panel for future comparisons to evaluate for MRD	
0307U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cellfree DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD	
0340U	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate	
0356U	Oncology (oropharyngeal or anal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence	
0422U	Oncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate	
0467U	Oncology (bladder), DNA, next-generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden	

0470U	Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. American Society for Radiation Oncology (ASTRO). Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: an ASTRO clinical practice guideline. <https://astro.org>. Published 2024.
2. American Society of Clinical Oncology (ASCO). Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. <https://asco.org>. Published March 5, 2018.
3. American Society of Clinical Oncology (ASCO). Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. <https://asco.org>. Published December 12, 2019.
4. Berger BM, Hanna GJ, Posner MR, et al. Detection of occult recurrent using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-drive oropharyngeal carcinoma. *Clin Cancer Res*. 2022;28(19):4292-4301.
5. Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. *J Clin Oncol*. 2019;37(18):1547-1557.
6. Coombes RC, Page K, Salari R, et al. Personalized detection of circulation tumor DNA antedates breast cancer metastatic recurrence. *Clin Cancer Res*. 2019;25(14):4255-4263.
7. ECRI Institute. Clinical Evidence Assessment. NavDx Assay (Naveris, Inc.) for aiding diagnosis of HPV-associated cancers. <https://home.ecri.org>. Published June 1, 2020. Updated March 2023.
8. ECRI Institute. Clinical Evidence Assessment. NavDx Assay (Naveris, Inc.) for detecting recurrence of HPV-associated cancers. <https://home.ecri.org>. Published March 2023.
9. ECRI Institute. Clinical Evidence Assessment. NavDx Assay (Naveris, Inc.) for managing HPV-associated cancer treatment decisions. <https://home.ecri.org>. Published March 2023.

10. ECRI Institute. ECRI Genetic Test Assessment. Circulating tumor DNA tests for colorectal cancer minimal residual disease. <https://home.ecri.org>. Published November 2022.
11. ECRI Institute. ECRI Genetic Test Assessment. clonoSEQ Assay (Adaptive Biotechnologies) for assessing prognosis of blood cancers and monitoring minimal residual disease. <https://home.ecri.org>. Published August 2022.
12. ECRI Institute. ECRI Genetic Test Assessment. Guardant Reveal (Guardant Health, Inc.) liquid biopsy test for assessing minimal residual disease and monitoring recurrence of colorectal cancer. <https://home.ecri.org>. Published April 2022.
13. ECRI Institute. ECRI Genetic Test Assessment. Signatera (Natera, Inc.) for assessing molecular residual disease and monitoring recurrence of colorectal cancer. <https://home.ecri.org>. Published June 2023.
14. Hanna GJ, Roof SA, Jabalee J, et al. Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance. *Clin Cancer Res*. 2023;29(20):4306-4313.
15. Hayes, Inc. Molecular Test Assessment. clonoSEQ (Adaptive Biotechnologies). <https://evidence.hayesinc.com>. Published June 22, 2022. Updated June 17, 2024.
16. Hayes, Inc. Molecular Test Assessment. NavDx (Naveris). <https://evidence.hayesinc.com>. Published August 15, 2023. Updated September 10, 2024.
17. Hayes, Inc. Molecular Test Assessment. Signatera (Natera Inc.). <https://evidence.hayesinc.com>. Published January 18, 2023. Updated March 19, 2025.
18. Hayes, Inc. Precision Medicine Research Brief. Guardant Reveal (Guardant Health). <https://evidence.hayesinc.com>. Published March 20, 2023.
19. Hou J, Chapman J, Kalashnikova E, et al. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. *Gynecol Oncol*. 2022;167(2):334-341.
20. Huffman BM, Singh H, Ali LR, et al. Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders. *J Immunother Cancer*. 2024;12(1):e008436.
21. Janni W, Rack B, Friedl TWP, et al. Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay. *ESMO Open*. 2025;10(4):104296.
22. Kasi PM, Chakrabarti S, Sawyer S, et al. BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. *BMJ Open*. 2022;12(5):e060342.
23. Larribere L, Martens UM. Advantages and challenges of using ctDNA NGS to assess the presence of minimal residual disease (MRD) in solid tumors. *Cancers (Basel)*. 2021;13(22):5698.

24. Liu JC, Y HJ. A review of the pharmacokinetic characteristics of immune checkpoint inhibitors and their clinical impact factors. *Pharmgenomics Pers Med*. 2023;16:29-36.
25. Loupakis F, Sharma S, Derouazi M, et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases. *JCO Precis Oncol*. 2021;5:PO.21.00101.
26. Nagasaka M, Uddin MH, Al-Hallak MN, et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. *Mol Cancer*. 2021;20(1):82.
27. Nakamura Y, Tsukada Y, Matsushashi N, et al. Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay. *Clin Cancer Res*. 2024;30(19):4377-4387.
28. Nakamura Y, Watanabe J, Akazawa N, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. *Nat Med*. 2024;30(11):3272-3283.
29. National Comprehensive Cancer Network (NCCN). NCCN Biomarkers Compendium: minimal residual disease testing. <https://nccn.org>. Updated 2025.
30. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. <https://nccn.org>. Updated January 27, 2025.
31. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bladder cancer. <https://nccn.org>. Updated March 25, 2025.
32. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer. <https://nccn.org>. Updated April 17, 2025.
33. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon cancer. <https://nccn.org>. Updated June 27, 2025.
34. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Head and neck cancers. <https://nccn.org>. Updated June 20, 2025.
35. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Multiple myeloma. <https://nccn.org>. Updated July 16, 2025.
36. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. <https://nccn.org>. Updated July 10, 2025.
37. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer. <https://nccn.org>. Updated July 16, 2025.

38. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Rectal cancer. <https://nccn.org>. Updated March 31, 2025.
39. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. *Clin Cancer Res*. 2021;27(20):5586-5594.
40. Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. *JAMA Oncol*. 2019;5(8):1124-1131.
41. Sanz-Garcia E, Xou J, Avery L, et al. Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck. *Cell Death Differ*. 2024;31(4):460-468.
42. Sfakianos JP, Basu A, Laliotis G, et al. Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer. *Eur Urol Oncol*. 2025;8(2):306-314.
43. Thompson JC, Carpenter EL, Silva BA, et al. Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. *JCO Precis Oncol*. 2021;5:PO.20.00321.
44. US Food & Drug Administration (FDA). 510(k) decision summary: Adaptive Biotechnologies ClonoSEQ Assay. <https://fda.gov>. Published August 5, 2020.
45. US Food & Drug Administration (FDA). De novo decision summary: clonoSEQ Assay. <https://fda.gov>. Published September 28, 2018.
46. US Food & Drug Administration (FDA). Laboratory developed tests. <https://fda.gov>. Updated February 4, 2025.
47. Wierda WG, Rawstron A, Cymbalista F, et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. *Leukemia*. 2021;35(11):3059-3072.
48. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. *Cancer Discov*. 2020;10(12):1842-1853.

Molecular Markers in Fine Needle Aspirates of Thyroid Nodules

Description

Laboratory examination of cells in thyroid nodules acquired through fine needle aspiration (FNA) has been proposed to assist in exploring the possibility of thyroid cancer. These tests are used to detect molecular markers that are associated with thyroid cancer and are performed when cytopathology cannot determine if the nodule is malignant or benign. This classification is referred to as indeterminate.

Thyroid nodules are abnormal growths or lumps that develop in the thyroid gland. While most are benign, a small percentage are malignant. To determine the likelihood of malignancy, FNA is used to obtain cells from the nodule that is evaluated by cytopathology. FNA results are then assigned to one of 5 categories based on a classification system known as The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). Results categorized as indeterminate warrant further evaluation, which may include repeat FNA, thyroid surgery and/or histopathology. Even with the additional examinations, most cases are ultimately classified as benign. Testing for molecular markers in specimens already attained via FNA potentially eliminates the need for repeat FNA or for surgery.

Thyroid GuidePx is a gene expression profiling test intended for the evaluation of risk for recurrence for an individual with papillary thyroid carcinoma. The test stratifies an individual with papillary thyroid carcinoma into three molecular subgroups and uses a proprietary algorithm to determine risk of recurrence.

ThyroSeq v3 Cancer Risk Classifier (CRC) uses next-generation sequencing (NGS) to analyze the DNA and RNA of over 100 genes in cytologically malignant FNA or resected thyroid tissue to aid in determining risk of recurrence.

Testing for molecular markers in thyroid nodules specimens differs from germline genetic mutation testing. Analysis of molecular markers evaluates specimens for mutations acquired over an individual's lifetime and are present only in the tissue sampled. Germline DNA is constant and identical in all body tissue types and mutations are inheritable.

Coverage Determination

There are no covered indications; refer to Coverage Limitations Section.

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for **molecular markers in thyroid nodule specimens obtained by FNA** for any indications or tests other than those listed above including, but may not be limited to:

- Afirma XA (0204U)
- ThyroSeq v3 Cancer Risk Classifier (CRC) (0287U)

- Use of more than one molecular marker assay

A review of the current medical literature shows that the **evidence is insufficient** to determine that this service is standard medical treatment. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of this service in clinical management.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
0018U	Oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy	
0026U	Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy")	
0245U	Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers using next-generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage	
0287U	Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high)	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. American Association of Clinical Endocrinologists (AACE). AACE/ACE/AME Guidelines. American Association of Clinical Endocrinology, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules – 2016 update. <https://aace.com>. Published May 2016.
2. American Association of Clinical Endocrinologists (AACE). White Paper. American Association of Clinical Endocrinology and Associazione Medici Endocrinologi thyroid nodule algorithmic tool. <https://aace.com>. Published 2021.
3. American Thyroid Association (ATA). American Thyroid Association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making. <https://thyroid.org>. Published July 10, 2015.
4. American Thyroid Association (ATA). Special Articles. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. <https://thyroid.org>. Published January 12, 2016.
5. Bardet S, Goardon N, Lequesne J, et al. Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study. *Endocrine*. 2021;71(2):407-417.
6. Carr DM, Mastorides S, Stobaugh C, Carlton G, DeLand L, Borkowski A. Molecular testing of atypical thyroid nodules with corresponding surgical correlation: five-year retrospective review in veterans population. *Cureus*. 2022;14(2):e22536.
7. Ciarletto AM, Narick C, Malchoff CD, et al. Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine-needle aspiration samples. *Cancer Cytopathol*. 2021;129(3):239-249.
8. ClinicalKey. Clinical Overview. Thyroid nodule. <https://clinicalkey.com>. Updated January 1, 2024.
9. Craig S, Stretch C, Farshidfar F, et al. A clinically useful and biologically informative genomic classifier for papillary thyroid cancer. *Front Endocrinol (Lausanne)*. 2023;14:1220617.
10. ECRI Institute. ECRIgene Evidence Report. Thyroid Gene Expression Classifier (Afirma) for assessing indeterminate thyroid nodules. <http://home.ecri.org>. Published May 2018.
11. ECRI Institute. ECRIgene Genetic Test Assessment. Thyroid GuidePx assay (Qualisure Diagnostics) for evaluating prognosis and guiding management of papillary thyroid cancer. <https://home.ecri.org>. Published April 2023.
12. ECRI Institute. ECRIgene Genetic Test Product Brief. ThyGenX Oncogene Panel Plus ThyraMIR microRNA Classifier (Interpace Diagnostics, LLC) for evaluating cytologically indeterminate thyroid nodules. <https://home.ecri.org>. Published January 2020.

13. ECRI Institute. ECRIgene Genetic Test Product Brief. ThyroSeq v.3 (University of Pittsburgh Medical Center) for evaluating cytologically indeterminate thyroid nodules. <https://home.ecri.org>. Published January 2020.
14. Gallant JN, Chen SC, Ortega CA, et al. Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children. *JAMA Oncol*. 2022;8(9):1323-1327.
15. Gargano SM, Badjatia N, Nikolaus Y, Peiper SC, Wang ZX. Characterization and clinical significance of EIF1AX mutations and co-mutations in cytologically indeterminate thyroid nodules: a 5-year retrospective analysis. *Acta Med Acad*. 2021;50(1):4-12.
16. Gokozan HN, Dilcher TL, Alperstein SA, et al. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory. *Cancer Cytopathol*. 2022;130(4):259-274.
17. Hayes, Inc. Molecular Test Assessment. ThyGeNEXT and ThyraMIR (Interpace Diagnostics Group Inc). <https://evidence.hayesinc.com>. Published July 10, 2019. Updated October 21, 2022.
18. Hayes, Inc. Molecular Test Assessment. ThyroSeq v3 (University of Pittsburgh Medical Center, CBLPath). <https://evidence.hayesinc.com>. Published March 8, 2023. Updated March 19, 2025.
19. Hu C, Jing W, Chang Q, et al. Risk stratification of indeterminate thyroid nodules by novel multigene testing: a study of Asians with a high risk of malignancy. *Mol Oncol*. 2022;16(8):1680-1693.
20. Hu MI, Waguespack SG, Dosiou C, et al. Afirma Genomic Sequencing Classifier and Xpression Atlas molecular findings in consecutive Bethesda III-VI thyroid nodules. *J Clin Endocrinol Metab*. 2021;13;106(8):2198-2207.
21. Kaya C, Dorsaint, P, Mercurio S, et al. Limitations of detecting genetic variants from the RNA sequencing data in tissue and fine-needle aspiration samples. *Thyroid*. 2021;31(4):589-595.
22. Kim TH, Jeong DJ, Hahn SY, et al. Triage of patients with AUS/FLUS on thyroid cytopathology: effectiveness of the multimodal diagnostic techniques. *Cancer Med*. 2016;5(5):769-777.
23. Lu SY, Chen YC, Zhu CF, et al. A five-gene panel refines differential diagnosis of thyroid nodules. *J Clin Lab Anal*. 2021;35(9):e23920.
24. Napoli F, Rapa I, Mortara U, et al. MicroRNA profiling predicts positive nodal status in papillary thyroid carcinoma in the preoperative setting. *Cancer Cytopathol*. 2022;130(9):695-704.
25. National Comprehensive Cancer Network (NCCN). NCCN Biomarkers Compendium. Thyroid carcinoma. <https://nccn.org>. Updated 2025.
26. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma. <https://nccn.org>. Updated March 27, 2025.

27. O'Connor CJ, Dash RC, Jones CK, Jiang XS. Performance of repeat cytology with reflex ThyroSeq genomic classifier for indeterminate thyroid cytology. *Cancer Cytopathol*. 2022;130(6):469-476.
28. Salameh S, Rajab M, Forest VI, Pusztaszeri M, Payne RJ. Surgical outcomes of thyroid nodules positive for gene expression alterations using ThyroSeq V3 Genomic Classifier. *Cancers (Basel)*. 2022;15(1):49.
29. Schumm MA, Shu ML, Hughes EG, et al. Prognostic value of preoperative molecular testing and implications for initial surgical management in thyroid nodules harboring suspected (Bethesda V) or known (Bethesda VI) papillary thyroid cancer. *JAMA Otolaryngol Head Neck Surg*. 2023;149(8):735-742.
30. Silaghi CA, Lozovanu V, Georgescu CE, et al. Thyroseq v3, Afirma GSC, and microRNA panels versus previous molecular tests in the preoperative diagnosis of indeterminate thyroid nodules: a systematic review and meta-analysis. *Front Endocrinol (Lausanne)*. 2021;12:649522.
31. Sistrunk JW, Shifrin A, Frager M, et al. Clinical impact of testing for mutations and microRNAs in thyroid nodules. *Diagn Cytopathol*. 2019;47(8):758-764.
32. Skaugen JM, Taneja C, Liu JB, et al. Performance of a multigene genomic classifier in thyroid nodules with suspicious for malignancy cytology. *Thyroid*. 2022;32(12):1500-1508.
33. UpToDate, Inc. Atlas of thyroid cytopathology. <https://uptodate.com>. Updated June 2025.
34. UpToDate, Inc. Diagnostic approach to and treatment of thyroid nodules. <https://uptodate.com>. Updated June 2025.
35. UpToDate, Inc. Evaluation and management of thyroid nodules with indeterminate cytology. <https://uptodate.com>. Updated June 2025.
36. UpToDate, Inc. Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer. <https://uptodate.com>. Updated June 9, 2025.
37. UpToDate, Inc. Papillary thyroid cancer: clinical features and prognosis. <https://uptodate.com>. Updated June 2025.
38. Valderrabano P, Hallanger-Johnson JE, Thapa R, Wang X, McIver B. Comparison of postmarketing findings vs the initial clinical validation findings of a thyroid nodule gene expression classifier: a systematic review and meta-analysis. *JAMA Otolaryngol Head Neck Surg*. 2019;e191449.
39. Yip L, Gooding WE, Nikitski A, et al. Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study. *Cancer*. 2021;127(11):1779-1787.

Description

Multianalyte assays with algorithmic analyses (MAAAs) are laboratory measurements that use a mathematic formula to analyze multiple markers that may be associated with a particular disease state and are designed to evaluate disease activity or an individual's risk for disease. The laboratory performs an algorithmic analysis using the results of the assays and sometimes other individual information, such as gender and age and converts the information into a numeric score, which is conveyed on a laboratory report. Generally, MAAAs are exclusive (and/or proprietary) to a single laboratory which owns the algorithm. MAAA testing is used to aid in the diagnosis and evaluation of malignancies such as the following:

- **Lung Cancer**

- **Novify CDT test** is intended to detect early-stage lung cancer in an individual who is at moderate to high risk. The test measures the presence of 7 autoantibodies (CAGE, GBU4-5, HuD, MAGE A4, NY-ESO-1, p53 and SOX-2) that are asserted to be involved in early stages of lung cancer development. Results are to be used in conjunction with other clinical data to determine the appropriate diagnostic follow up.
- **LungOI** is an artificial-intelligence (AI)-based molecular profiling that uses a digitized biopsy image and is proposed for the diagnosis of lung cancer.
- **VeriStrat** is a serum-based mass spectrometric, eight proteins, including amyloid A, signature proteomic test. It is intended to aid in evaluating prognosis and predicting response to systemic or targeted therapies in an individual with advanced NSCLC.

- **Neuroendocrine Tumors**

- **NETest** is a multianalyte algorithm, polymerase chain reaction (PCR)-based gene blood test that measures 51 neuroendocrine tumor specific gene transcripts in combination with molecular biomarkers which purportedly allows monitoring of neuroendocrine tumor gene activity levels.

- **Ovarian Cancer**

- **OvaSuite** is a collection of blood tests (Ova1 Plus [Ova1 and Overa] and OvaWatch) proposed to assess risk of ovarian cancer in an individual diagnosed with an adnexal mass. Proprietary algorithms are applied, along with an individual's features as well as the levels of certain biomarkers. These biomarkers include apolipoprotein A1 (Apo A-1), beta-2 microglobulin (B2M), CA-125, follicle stimulating hormone (FSH), human epididymis protein (HE4), prealbumin and transferrin (TRF). Each test has a specific indication:
- **Ova1 Plus is comprised of Ova1 and Overa.** Ova1, an FDA-approved test, is performed for an individual with adnexal mass when surgery has been scheduled. If an individual has an intermediate risk result, Overa is automatically reflexed (performed in succession of original test).

- **Risk of Ovarian Malignancy Algorithm (ROMA)** is an FDA-approved blood test that measures HE4 and CA-125 to evaluate an individual with an adnexal mass to purportedly determine the likelihood of ovarian cancer.
- **Prostate Cancer**
 - **EpiSwitch Prostate Screening Test (PSE)** is a blood test that is used in combination with an individual's PSA score and measures 5 epigenetic biomarkers to determine the likelihood of prostate cancer.

Coverage Determination

There are no covered indications; refer to Coverage Limitations Section.

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for any of the following **MAAAs tests**:

- EpiSwitch Prostate Screening Test (PSE) (0433U)
- LungOI (0414U)
- NETest (0007M)
- Nodify CDT (0360U)
- OVA1 (81503)
- ROMA (81500)
- Veristrat (81538)

A review of the current medical literature shows that the **evidence is insufficient** to determine that this service is standard medical treatment. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of this service in clinical management.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81500	Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score	

81503	Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score	
81538	Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival	
0007M	Oncology (gastrointestinal neuroendocrine tumors), real-time PCR expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index	
0021U	Oncology (prostate), detection of 8 autoantibodies (ARF 6, NKX3-1, 5'-UTR-BMI1, CEP 164, 3'-UTR-Ropporin, Desmocollin, AURKAIP-1, CSNK2A2), multiplexed immunoassay and flow cytometry serum, algorithm reported as risk score	
0360U	Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy	
0414U	Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffin-embedded (FFPE) tissue, reported as positive or negative for each biomarker	
0433U	Oncology (prostate), 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer	
0465U	Oncology (urothelial carcinoma), DNA, quantitative methylation-specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. American College of Obstetricians and Gynecologists (ACOG). Committee Opinion. The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. <https://acog.org>. Published September 2017. Updated 2024.
2. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin. Evaluation and management of adnexal masses. <https://acog.org>. Published November 2016. Updated 2021.
3. Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. *Gynecol Oncol*. 2013;128(2):252-259.
4. Coleman RL, Herzog TJ, Chan DW, et al. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. *Am J Obstet Gynecol*. 2016;215(1):82.e1-82.e11.
5. ECRI Institute. Genetic Test Assessment. NETest (Wren Laboratories, LLC) to aid diagnosis and monitor treatment response for neuroendocrine tumors. <https://home.ecri.org>. Published November 2021.
6. ECRI Institute. Genetic Test Assessment. Nodify CDT (Biodesix, Inc.) for evaluating pulmonary nodules. <https://home.ecri.org>. Published February 2022.
7. ECRI Institute. Genetic Test Assessment. Risk of Ovarian Malignancy Algorithm (ROMA) (Fujirebio Diagnostics, Inc.) to assess the risk of malignancy of an ovarian mass. <https://home.ecri.org>. Published September 2021.
8. ECRI Institute. Genetic Test Assessment. VeriStrat (Biodesix, Inc.) to assess non-small cell lung cancer prognosis and predict response to platinum-based chemotherapy or EGFR tyrosine kinase inhibitors. <https://home.ecri.org>. Published November 2021.
9. Grossi F, Rijavec E, Genova C, et al. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. *Br J Cancer*. 2017;36-43.
10. Hayes, Inc. Precision Medicine Research Brief. EpiSwitch Checkpoint inhibitor Response Test (CiRT) (Oxford BioDynamics PLC). <https://evidence.hayesinc.com>. Published February 16, 2024.
11. Hayes, Inc. Molecular Test Assessment. Nodify CDT (Biodesix Inc.). <https://evidence.hayesinc.com>. Published April 20, 2021. Updated June 25, 2024.
12. Hayes, Inc. Molecular Test Assessment. OVA1 (ASPiRA Labs). <https://evidence.hayesinc.com>. Published December 19, 2017. Updated August 1, 2021.
13. Hayes, Inc. Molecular Test Assessment. VeriStrat (Biodesix Inc.). <https://evidence.hayesinc.com>. Published May 28, 2025.
14. Lemieux ME, Reveles XT, Rebeles J, et al. Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning. *Respir Res*. 2023;24(1):23.

15. Li F, Tie R, Chang K, et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. *BMC Cancer*. 2012;12:258.
16. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. *Gynecol Oncol*. 2009;112(1):40-6.
17. Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. *Obstet Gynecol*. 2011;118(2 Pt 1):280-288.
18. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine and adrenal tumors. <https://nccn.org>. Updated May 28, 2025.
19. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. <https://nccn.org>. Updated May 23, 2025.
20. Oberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. *Ann Oncol*. 2020;31(2):202-212.
21. Sethi S, Cicens J. Role of biomarkers in lung nodule evaluation. *Curr Opin Pulm Med*. 2022;28(4):275-281.
22. Silvestri G, Tanner N, Kearney P, et al. Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules results of the PANOPTIC (pulmonary nodule plasma proteomic classifier) trial. *Chest*. 2018;154(3):491-500.
23. UpToDate, Inc. Adnexal mass: role of serum biomarkers in diagnosing epithelial carcinoma of the ovary, fallopian tube, or peritoneum. <https://uptodate.com>. Updated June 2025.
24. UpToDate, Inc. Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors. <https://uptodate.com>. Updated June 2025.
25. US Food & Drug Administration (FDA). 510(k) summary: OVA1 Next Generation. <https://fda.gov>. Published March 18, 2016.
26. US Food & Drug Administration (FDA). 510(k) summary: ROMA (HE4 EIA + ARCHITECT CA 125 II). <https://fda.gov>. Published September 1, 2011.

SOLID TUMORS

Comprehensive Genomic Profiling and Multigene Panel Testing

Description

Comprehensive genomic profiling (CGP) (also referred to as comprehensive molecular profiling or tumor profiling) is a laboratory diagnostic method used to analyze the genetic makeup of solid tumors. CGP examines a wide range of genetic variations including mutations, insertions, deletions, amplifications and rearrangements across hundreds of genes. CGP can help guide targeted treatment options. Some CGP tests analyze DNA to detect genetic alterations. These DNA-based tests focus on identifying somatic mutations which occur in tumor cells and are not inherited. Examples include, but are not limited to, **Guardant360 TissueNext, MSK-IMPACT, Oncotype MAP Pan-Cancer Tissue Test and PGDx elio tissue complete**.

Companion diagnostics are laboratory tests that are co-developed with a specific drug to help evaluate if an individual with a specific condition (typically cancer) may benefit from the drug. Companion diagnostics are approved by the US Food & Drug Administration (FDA) typically at the same time as the corresponding pharmacotherapy and can include CGP, molecular biomarker assays as well as single and multigene panel tests. Examples of FDA-approved companion diagnostics include, **MI Cancer Seek, MyChoice CDx and Oncomine Dx Target Test**.

Cytogenomic neoplasia microarray analysis is a laboratory test that identifies abnormalities in chromosome structure and has been proposed for the diagnosis of cancer. Examples include, but are not limited to, **Clarisure Oligo-SNP and Oncoscan**.

Optical genome mapping, transcriptome, whole exome sequencing (WES) and whole genome sequencing (WGS) are other laboratory methods that have been proposed to profile tumors. These techniques purportedly identify genetic variants in an individual's cancer cells to potentially identify actionable genomic mutations to assist with selection of targeted therapies to treat cancer. Examples include, but are not limited to, **EXaCT-1 Whole Exome Sequencing, Praxis Somatic Combined Whole Genome Sequencing and Optimal Genome Mapping, Praxis Somatic Transcriptome and Praxis Somatic Whole Genome Sequencing**.

Coverage Determination

Chromosomal Microarray

Humana members may be eligible under the Plan for **chromosomal microarray (81277)** for the following indications:

- Evaluation of indeterminate melanocytic neoplasms following histopathology; **OR**
- Neuroblastoma

Comprehensive Genomic Profiling

Humana members may be eligible under the Plan for **comprehensive genomic profiling for solid tumors (81449, 81455, 81456)** for any of the following tests when the criteria below are met:

- ExaCT-1 Whole Exome Testing (0036U); **OR**
- Guardant360 Tissue Next (0334U); **OR**
- MSK-IMPACT (0048U); **OR**
- Oncotype MAP PanCancer Tissue Test (0244U); **OR**

- Oncomap ExTra (0329U); **OR**
- PGDx elio tissue complete (0250U);

AND both of the following:

- Individual to be tested has been diagnosed with recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; **AND**
- Individual has decided to seek further cancer treatment (eg, therapeutic chemotherapy)

MI Cancer Seek

Humana members may be eligible under the Plan for MI Cancer Seek (0211U) when the following criteria are met:

- Individual to be tested has been diagnosed with recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; **AND**
- Individual decided to seek further cancer treatment (eg, therapeutic chemotherapy); **AND**
- Individual to be tested for an indication with a corresponding FDA-approved gene or biomarker that establishes eligibility for treatment with a clinically relevant FDA-approved targeted therapy ([Table 1](#))

Table 1

MI Cancer Seek FDA-Approved Indications (The FDA frequently updates the [List of Cleared or Approved Companion Diagnostic Devices Website](#) with approvals for companion diagnostics.

Cancer	Indication(s)	Biomarker(s)	FDA-Approved Therapy Under Consideration
Breast Cancer	Metastatic	<i>PIK3CA</i>	Alpelisib (Piqray)
Colorectal Cancer	Metastatic	<i>KRAS</i> <i>NRAS</i>	Panitumumab (Vectibix)
Colorectal Cancer	Metastatic	<i>BRAF V600E</i>	Encorafenib (Braftovi) with cetuximab (Erbix)
Endometrial Carcinoma	Advanced	Not MSI-High	Pembrolizumab (Keytruda) with lenvatinib (Lenvima)
Melanoma	Metastatic or unresectable	<i>BRAF V600E</i>	Dabrafenib (Tafinlar)
Melanoma	Metastatic or unresectable	<i>BRAF V600E</i>	Vemurafenib (Zelboraf)
Melanoma	Metastatic or unresectable	<i>BRAF V600E</i> <i>BRAF V600K</i>	Cobimetinib (Cotellic) with vemurafenib (Zelboraf)
Melanoma	Stage III and has undergone lymph node resection, unresectable or stage IV metastatic	<i>BRAF V600E</i> <i>BRAF V600K</i>	Dabrafenib (Tafinlar) with trametinib (Mekinist)

Melanoma	Unresectable or stage IV metastatic	<i>BRAF V600E</i> <i>BRAF V600K</i>	Encorafenib (Braftovi) with binimetinib (Mektovi)
Melanoma	Metastatic or unresectable	<i>BRAF V600E</i> <i>BRAF V600K</i>	Trametinib (Mekinist)
Non-Small Cell Lung Cancer (NSCLC)	Metastatic	<i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution mutations	Afatinib (Gilotrif)
NSCLC	Metastatic	<i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution mutations	Dacomitinib (Vizimpro)
NSCLC	Metastatic	<i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution mutations	Erlotinib (Tarceva)
NSCLC	Metastatic or recurrent	<i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution mutations	Gefitinib (Iressa)
NSCLC	Locally advanced or metastatic	<i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution mutations	Lazertinib (Lazcluze)
NSCLC	Advanced or metastatic	<i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution mutations	Osimertinib (Tagrisso)
Solid Tumors	Metastatic or unresectable	MSI-High	Pembrolizumab (Keytruda)
Solid Tumors	Advanced or recurrent	MSI-High	Dostarlimab-gxly (Jemperli)

MyChoice CDx

Humana members may be eligible under the Plan for **MyChoice CDx (0172U)** when the following criteria are met:

- Epithelial ovarian, fallopian tube or primary peritoneal cancer - advanced; **AND**
- Treatment with olaparib (Lynparza) is under consideration

Oncomine Dx Target Test

Humana members may be eligible under the Plan for **Oncomine Dx Target Test (0022U)** when the following criteria are met:

- Individual to be tested has been diagnosed with recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer^{Error! Reference source not found.}; **AND**
- Individual decided to seek further cancer treatment (eg, therapeutic chemotherapy)^{Error! Reference source not found.}; **AND**
- Individual to be tested for an indication with a corresponding FDA-approved gene or biomarker that establishes eligibility for treatment with a clinically relevant FDA-approved targeted therapy ([Table 2](#))¹²¹

Table 2

Oncomine Dx Target Test FDA-Approved Indications (The FDA frequently updates the [List of Cleared or Approved Companion Diagnostic Devices Website](#) with approvals for companion diagnostics.

Cancer	Indication(s)	Biomarker(s)	FDA-Approved Therapy Under Consideration
Anaplastic thyroid cancer	Locally advanced or metastatic	<i>BRAF V600E</i>	Dabrafenib (Tafinlar) with trametinib (Mekinist)
Astrocytoma	Grade 2	<i>IDH1</i> <i>IDH2</i>	Vorasidenbi (Vorango)
Cholangiocarcinoma	Locally advanced or metastatic	<i>IDH1</i>	Ivosidenib (Tibsovo)
Medullary thyroid cancer	Advanced or metastatic	<i>RET</i>	Selpercatinib (Retevmo)
Non-small cell lung cancer (NSCLC)	Metastatic	<i>BRAF V600E</i>	Dabrafenib (Tafinlar) with trametinib (Mekinist)
NSCLC	Metastatic	<i>EGFR</i> exon 19 deletion or exon 21 L858R substitution mutation	Gefitinib (Iressa)

NSCLC	Locally advanced or metastatic	<i>EGFR</i> exon 20 insertion mutations	Amivantamab-vmjw (Rybrevant)
NSCLC	Unresectable or metastatic	<i>ERBB2 (HER2)</i>	Fam-trastuzumab deruxtecan-nxki (Enhertu)
NSCLC	Metastatic	<i>RET</i>	Pralsetinib (Gavreto)
NSCLC	Advanced or metastatic	<i>RET</i>	Selpercatinib (Retevmo)
NSCLC	Metastatic	<i>ROS1</i>	Crizotinib (Xalkori)
Oligodendroglioma	Grade 2	<i>IDH1</i> <i>IDH2</i>	Vorasidenbi (Voranigo)
Thyroid cancer	Advanced or metastatic	<i>RET</i>	Selpercatinib (Retevmo)

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for any of the following tests:

- Praxis Somatic Combined Whole Genome Sequencing and Optical Genome Mapping (0300U)
- Praxis Somatic Optical Genome Mapping Test (0299U)
- Praxis Somatic Transcriptome (0298U)
- Praxis Somatic Whole Genome Sequencing Test (0297U)

A review of the current medical literature shows that the **evidence is insufficient** to determine that this service is standard medical treatment. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of this service in clinical management.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81277	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities	
81449	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysis	

81455	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA an	
81456	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA an	
0022U	Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence or absence of variants and associated therapy(ies) to consider	
0036U	Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses	
0048U	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraff	
0172U	Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score	
0211U	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association	
0244U	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing fo	
0250U	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden	

0297U	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification	
0298U	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification	
0299U	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification	
0300U	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification	
0329U	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations	
0334U	Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. American Academy of Dermatology (AAD). Guidelines of care for the management of primary cutaneous melanoma. <https://aad.org>. Published January 2019.
2. American College of Medical Genetics and Genomics (ACMG). ACMG Technical Standard. Section E6.7-6.12 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory

Standards: cytogenomic studies of acquired chromosomal abnormalities in solid tumors.
<https://acmg.net>. Published 2024.

3. American Society of Clinical Oncology (ASCO). Biomarkers for systemic therapy in metastatic breast cancer guideline and rapid update. <https://asco.org>. Updated February 6, 2024.
4. American Society of Clinical Oncology (ASCO). Endocrine treatment and targeted therapy for HR-positive, HER2-negative metastatic breast cancer guideline and rapid update. <https://asco.org>. Published February 22, 2016. Updated February 18, 2025.
5. American Society of Clinical Oncology (ASCO). Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline. <https://asco.org>. Published January 9, 2025.
6. American Society of Clinical Oncology (ASCO). Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO guideline. <https://asco.org>. Published December 15, 2022.
7. American Society of Clinical Oncology (ASCO). Metastatic pancreatic cancer: ASCO guideline update. <https://asco.org>. Published August 5, 2020.
8. American Society of Clinical Oncology (ASCO). Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline. <https://asco.org>. Published January 5, 2023.
9. American Society of Clinical Oncology (ASCO). Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology clinical practice guideline update. <https://asco.org>. Published February 5, 2018.
10. American Society of Clinical Oncology (ASCO). Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. <https://asco.org>. Published August 25, 2022.
11. American Society of Clinical Oncology (ASCO). Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. <https://asco.org>. Published February 10, 2022. Updated February 24, 2025.
12. American Society of Clinical Oncology (ASCO). Treatment of metastatic colorectal cancer: ASCO guideline. <https://asco.org>. Published October 17, 2022.
13. American Society of Clinical Oncology (ASCO). Treatment of pleural mesothelioma: ASCO guideline update. <https://asco.org>. Published January 8, 2025.

14. American Thyroid Association (ATA). 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer: American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force. <https://thyroid.org>. Published 2021.
15. American Thyroid Association (ATA). Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. <https://thyroid.org>. Published 2015.
16. American Urological Association (AUA). Advanced prostate cancer: AUA/SUO guideline. <https://auanet.org>. Published 2020. Updated 2023.
17. Association for Molecular Pathology (AMP). Molecular biomarkers for the evaluation of colorectal cancer. <https://amp.org>. Published March 2017.
18. Association for Molecular Pathology (AMP). Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. <https://amp.org>. Published March 2013.
19. College of American Pathologists (CAP). Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy statements and strengths of recommendations: guideline From the College of American Pathologists in collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer. <https://cap.org>. Published August 3, 2022.
20. College of American Pathologists (CAP). Molecular biomarker testing for the diagnosis of diffuse gliomas: guideline from the College of American Pathologists in collaboration with the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology. <https://cap.org>. Published May 2022.
21. College of American Pathologists (CAP). Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. <https://cap.org>. Published May 2017.
22. Freedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States. *JCO Precis Oncol*. 2018;2:PO.18.00169.
23. Hayes, Inc. Precision Medicine Research Brief. Guardant360 TissueNext (Guardant Health Inc.). <https://evidence.hayesinc.com>. Published May 3, 2023.
24. Hayes, Inc. Precision Medicine Research Brief. MI Cancer Seek (Caris Life Sciences). <https://evidence.hayesinc.com>. Published March 18, 2025.
25. Hayes, Inc. Precision Medicine Research Brief. MyChoice CDx (Myriad Genetics Inc.). <https://evidence.hayesinc.com>. Published October 14, 2022.

26. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Biliary tract cancers. <https://nccn.org>. Updated January 10, 2025.
27. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bladder cancer. <https://nccn.org>. Updated January 17, 2025.
28. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer. <https://nccn.org>. Updated April 17, 2025.
29. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Central nervous system cancers. <https://nccn.org>. Updated January 21, 2025.
30. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. <https://nccn.org>. Updated January 31, 2025.
31. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon cancer. <https://nccn.org>. Updated April 24, 2025.
32. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Esophageal and esophagogastric junction cancers. <https://nccn.org>. Updated December 20, 2024.
33. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Gastric cancer. <https://nccn.org>. Updated December 20, 2024.
34. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Gastrointestinal stromal tumors. <https://nccn.org>. Updated July 31, 2024.
35. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: colorectal, endometrial, and gastric. <https://nccn.org>. Updated October 31, 2024.
36. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Head and neck cancers. <https://nccn.org>. Updated January 17, 2025.
37. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Hepatocellular carcinoma. <https://nccn.org>. Updated January 10, 2025.
38. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Melanoma: cutaneous. <https://nccn.org>. Updated January 28, 2025.
39. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Neuroblastoma. <https://nccn.org>. Updated July 2, 2024.
40. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine and adrenal tumors. <https://nccn.org>. Updated January 17, 2025.

41. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. <https://nccn.org>. Updated January 14, 2025.
42. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Occult primary (cancer of unknown primary [CUP]). <https://nccn.org>. Updated September 11, 2024.
43. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. <https://nccn.org>. Updated July 16, 2025.
44. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma. <https://nccn.org>. Updated December 20, 2024.
45. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. <https://nccn.org>. Updated December 4, 2024.
46. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Rectal cancer. <https://nccn.org>. Updated March 31, 2025.
47. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Thyroid carcinoma. <https://nccn.org>. Updated January 15, 2025.
48. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Uterine neoplasms. <https://nccn.org>. Updated March 7, 2025.
49. Rennert H, Eng K, Zhang T, et al. Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. *NPJ Genom Med*. 2016;1: 16019.
50. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. <https://sitcancer.org>. Published August 13, 2021.
51. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. <https://sitcancer.org>. Published June 7, 2023.
52. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. <https://sitcancer.org>. Published June 9, 2023.
53. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. <https://sitcancer.org>. Published May 31, 2022.

54. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. <https://sitcancer.org>. Published October 18, 2023.
55. UpToDate, Inc. Adenocarcinoma of unknown primary site. <https://uptodate.com>. Updated January 2025.
56. UpToDate, Inc. Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors. <https://uptodate.com>. Updated January 2025.
57. UpToDate, Inc. Anaplastic thyroid cancer. <https://uptodate.com>. Updated January 2025.
58. UpToDate, Inc. Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors. <https://uptodate.com>. Updated January 2025.
59. UpToDate, Inc. Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas. <https://uptodate.com>. Updated January 2025.
60. UpToDate, Inc. Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors. <https://uptodate.com>. Updated January 2025.
61. UpToDate, Inc. Initial systemic therapy for advanced non-small cell lung cancer lacking a driver mutation. <https://uptodate.com>. Updated January 2025.
62. UpToDate, Inc. Initial systemic therapy for metastatic colorectal cancer. <https://uptodate.com>. Updated January 21, 2025.
63. UpToDate, Inc. Initial systemic therapy for metastatic esophageal and gastric cancer. <https://uptodate.com>. Updated January 2025.
64. UpToDate, Inc. Initial systemic therapy for metastatic exocrine pancreatic cancer. <https://uptodate.com>. Updated January 25, 2025.
65. UpToDate, Inc. Malignant salivary gland tumors: treatment of recurrent and metastatic disease. <https://uptodate.com>. Updated January 2025.
66. UpToDate, Inc. Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency. <https://uptodate.com>. Updated January 2025.
67. UpToDate, Inc. Management of glioblastoma in older adults. <https://uptodate.com>. Updated January 21, 2025.
68. UpToDate, Inc. Management of ovarian cancer associated with BRCA and other genetic mutations. <https://uptodate.com>. Updated January 2025.

69. UpToDate, Inc. Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: platinum-resistant disease. <https://uptodate.com>. Updated January 2025.
70. UpToDate, Inc. Medullary thyroid cancer: systemic therapy and immunotherapy. <https://uptodate.com>. Updated January 2025.
71. UpToDate, Inc. Melanoma: clinical features and diagnosis. <https://uptodate.com>. Updated January 2025.
72. UpToDate, Inc. Metastatic uveal melanoma. <https://uptodate.com>. Updated January 2025.
73. UpToDate, Inc. Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer. <https://uptodate.com>. Updated January 2025.
74. UpToDate, Inc. Overview of advanced unresectable and metastatic solid tumors with DNA mismatch repair deficiency or high tumor mutational burden. <https://uptodate.com>. Updated January 2025.
75. UpToDate, Inc. Overview of the approach to metastatic breast cancer. <https://uptodate.com>. Updated January 2025.
76. UpToDate, Inc. Overview of the classification and management of cancers of unknown primary site. <https://uptodate.com>. Updated January 2025.
77. UpToDate, Inc. Overview of the initial treatment of advanced non-small cell lung cancer. <https://uptodate.com>. Updated January 2025.
78. UpToDate, Inc. Overview of the management of advanced cutaneous melanoma. <https://uptodate.com>. Updated January 2025.
79. UpToDate, Inc. Pathology and prognostic determinants of colorectal cancer. <https://uptodate.com>. Updated January 2025.
80. UpToDate, Inc. Personalized, genotype-directed therapy for advanced non-small cell lung cancer. <https://uptodate.com>. Updated January 22, 2025.
81. UpToDate, Inc. Poorly differentiated cancer from an unknown primary site. <https://uptodate.com>. Updated January 2025.
82. UpToDate, Inc. Principles of cancer immunotherapy. <https://uptodate.com>. Updated January 2025.
83. UpToDate, Inc. Prognostic and predictive factors in metastatic breast cancer. <https://uptodate.com>. Updated August 2024.
84. UpToDate, Inc. Second- and later-line systemic therapy for metastatic exocrine pancreatic cancer. <https://uptodate.com>. Updated January 31, 2025.

85. UpToDate, Inc. Second and later lines of therapy for metastatic soft tissue sarcoma. <https://uptodate.com>. Updated January 2025.
86. UpToDate, Inc. Systemic therapy for advanced unresectable and metastatic cholangiocarcinoma. <https://uptodate.com>. Updated January 2025.
87. UpToDate, Inc. Systemic treatment of metastatic melanoma with BRAF and other molecular alterations. <https://uptodate.com>. Updated January 2025.
88. UpToDate, Inc. Treatment of advanced unresectable and metastatic gallbladder cancer. <https://uptodate.com>. Updated January 2025.
89. UpToDate, Inc. Treatment for hormone receptor-positive, HER2-negative advanced breast cancer. <https://uptodate.com>. Updated January 31, 2025.
90. UpToDate, Inc. Treatment of metastatic breast cancer in older women. <https://uptodate.com>. Updated August 2024.
91. UpToDate, Inc. Treatment of metastatic urothelial cancer of the bladder and urinary tract. <https://uptodate.com>. Updated January 7, 2025.
92. UpToDate, Inc. TRK fusion-positive cancers and TRK inhibitor therapy. <https://uptodate.com>. Updated January 8, 2025.
93. UpToDate, Inc. Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors. <https://uptodate.com>. Updated January 2025.
94. US Food & Drug Administration (FDA). 510(k) premarket approval: PGDx elio tissue complete. <https://fda.gov>. Published April 24, 2020.
95. US Food & Drug Administration (FDA). De novo summary: MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets). <https://fda.gov>. Published November 15, 2017.
96. US Food & Drug Administration (FDA). Full prescribing information: Braftovi (encorafenib). <https://fda.gov>. Published 2018. Updated March 2025.
97. US Food & Drug Administration (FDA). Full prescribing information: Cotellic (cobimetinib). <https://fda.gov>. Published 2015. Updated May 2023.
98. US Food & Drug Administration (FDA). Full prescribing information: Enhertu (fam-trastuzumab deruxtecan-nxki). <https://fda.gov>. Published 2019. Updated April 2024.
99. US Food & Drug Administration (FDA). Full prescribing information: Erbitux (cetuximab). <https://fda.gov>. Published 2004. Updated September 2021.

100. US Food & Drug Administration (FDA). Full prescribing information: Gavreto (pralsetinib). <https://fda.gov>. Published 2020. Updated June 2024.
101. US Food & Drug Administration (FDA). Full prescribing information: Gilotrif (afatinib). <https://fda.gov>. Published 2013. Updated April 2022.
102. US Food & Drug Administration (FDA). Full prescribing information: Iressa (gefitinib). <https://fda.gov>. Published 2015. Updated May 2021.
103. US Food & Drug Administration (FDA). Full prescribing information: Jemperli (dostarlimab-gxly). <https://fda.gov>. Published 2021. Updated August 2024.
104. US Food & Drug Administration (FDA). Full prescribing information: Keytruda (pembrolizumab). <https://fda.gov>. Published 2014. Updated April 2025.
105. US Food & Drug Administration (FDA). Full prescribing information: Lazcluze (lazertinib). <https://fda.gov>. Published 2024. Updated August 2024.
106. US Food & Drug Administration (FDA). Full prescribing information: Lynparza (olaparib). <https://fda.gov>. Published 2014. Updated November 2023.
107. US Food & Drug Administration (FDA). Full prescribing information: Mekinist (trametinib). <https://fda.gov>. Published 2013. Updated April 2025.
108. US Food & Drug Administration (FDA). Full prescribing information: Mektovi (binimetinib). <https://fda.gov>. Published 2018. Updated October 2023.
109. US Food & Drug Administration (FDA). Full prescribing information: Piqray (alpelisib). <https://fda.gov>. Published 2019. Updated January 2024.
110. US Food & Drug Administration (FDA). Full prescribing information: Retevmo (selpercatinib). <https://fda.gov>. Published 2020. Updated September 2024.
111. US Food & Drug Administration (FDA). Full prescribing information: Rybrevant (amivantamab-vmjw). <https://fda.gov>. Published 2021. Updated September 2024.
112. US Food & Drug Administration (FDA). Full prescribing information: Tafinlar (dabrafenib). <https://fda.gov>. Published 2013. Updated April 2025.
113. US Food & Drug Administration (FDA). Full prescribing information: Tagrisso (osimertinib). <https://fda.gov>. Published 2015. Updated September 2024.
114. US Food & Drug Administration (FDA). Full prescribing information: Tarceva (erlotinib). <https://fda.gov>. Published 2004. Updated October 2016.

115. US Food & Drug Administration (FDA). Full prescribing information: Tibsovo (ivosidenib). <https://fda.gov>. Published 2018. Updated October 2023.
116. US Food & Drug Administration (FDA). Full prescribing information: Vectibix (panitumumab). <https://fda.gov>. Published 2006. Updated January 2025.
117. US Food & Drug Administration (FDA). Full prescribing information: Vizimpro (dacomitinib). <https://fda.gov>. Published 2018. Updated December 2020.
118. US Food & Drug Administration (FDA). Full prescribing information: Voranigo (vorasidenib). <https://fda.gov>. Published 2024. Updated August 2024.
119. US Food & Drug Administration (FDA). Full prescribing information: Xalkori (crizotinib). <https://fda.gov>. Published 2011. Updated September 2023.
120. US Food & Drug Administration (FDA). Full prescribing information: Zelboraf (vemurafenib). <https://fda.gov>. Published 2011. Updated May 2020.
121. US Food & Drug Administration (FDA). In vitro companion diagnostic devices. <https://fda.gov>. Published August 6, 2014.
122. US Food & Drug Administration (FDA). Laboratory developed tests. <https://fda.gov>. Updated October 30, 2024.
123. US Food & Drug Administration (FDA). List of cleared or approved companion diagnostic devices (in vitro and imaging tools). <https://fda.gov>. Updated March 5, 2025.
124. US Food & Drug Administration (FDA). Premarket approval. MI Cancer Seek. <https://fda.gov>. Published November 5, 2024.
125. US Food & Drug Administration (FDA). Premarket approval. Myriad MyChoice CDx. <https://fda.gov>. Published October 28, 2019. Updated May 8, 2020.
126. US Food & Drug Administration (FDA). Premarket approval. Oncomine Dx Target Test. <https://fda.gov>. Published June 22, 2017. Updated October 2024.

SOLID TUMORS

Single Gene Testing

Description

Single gene tests analyze only one gene for variants specific to cancer type. Examples of single gene tests include *FGFR*, *IDH1*, *IDH2*, *MGMT*, *PIK3CA* and *TERT*.

Coverage Determination

FGFR3 Gene Testing

Humana members may be eligible under the Plan for **FGFR3 gene testing (eg, theascreen FGFR RGQ RT-PCR Kit [0154U])** for the following indications:

- Bladder cancer – locally advanced, metastatic or unresectable; **AND**
 - To determine eligibility for treatment with erdafitinib (Balversa) or fam-trastuzumab deruxtecan (Enhertu); **OR**
- Salivary gland tumors - metastatic, recurrent, unresectable; **AND**
 - To determine clinical trial eligibility

IDH1 and IDH2 Gene Testing

Humana members may be eligible under the Plan for **IDH1 (81120) and/or IDH2 (81121) single gene testing** for the following indications:

- Cholangiocarcinoma - unresectable or metastatic (**IDH1 only**); **OR**
- Gallbladder cancer - unresectable or metastatic (**IDH1 only**); **OR**
- Glioma

MGMT Promoter Methylation Testing

Humana members may be eligible under the Plan for **MGMT promoter methylation testing (81287)** for glioma.

PIK3CA Gene Testing

Humana members may be eligible under the Plan for **PIK3CA gene testing (81309)** for the following indications:

- Breast cancer – advanced or metastatic; **AND**
 - Disease progression on or after endocrine-based therapy; **AND**
 - HR-positive and HER2-negative disease; **AND**
 - Test is FDA approved (**theascreen PIK3CA RGQ PCR Kit [0155U, 0177U]**); **AND**
 - To determine eligibility for treatment with either of the following:
 - Alpelisib (Piqray) in combination with fulvestrant (Faslodex); **OR**
 - Inavolisib (Itovebi) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex); **OR**

- Breast cancer; **AND**
 - Disease progression on or after endocrine-based therapy; **AND**
 - HR-positive and HER2-negative disease; **AND**
 - To determine eligibility for treatment with alpelisib (Piqray) in combination with fulvestrant (Faslodex)

TERT Gene Testing

Humana members may be eligible under the Plan for **TERT gene testing (81345)** for the following indications:

- Glioma; **OR**
- Melanoma, cutaneous; **OR**
- Uterine carcinoma

Coverage Limitations

There are no limitations; refer to Coverage Determination Section.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81120	IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common variants (eg, R132H, R132C)	
81121	IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (eg, glioma), common variants (eg, R140W, R172M)	
81287	MGMT (O-6-methylguanine-DNA methyltransferase) (eg, glioblastoma multiforme) promoter methylation analysis	
81309	PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, 20)	
81345	TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)	

0154U	Oncology (urothelial cancer), RNA, analysis by real-time RT-PCR of the FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3) utili	
0155U	Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H10	
0177U	Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as PIK3CA gene mutation status	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. American Academy of Dermatology (AAD). Guidelines of care for the management of primary cutaneous melanoma. <https://aad.org>. Published January 2019.
2. American Society of Clinical Oncology (ASCO). Biomarkers for systemic therapy in metastatic breast cancer guideline and rapid update. <https://asco.org>. Updated February 6, 2024.
3. American Society of Clinical Oncology (ASCO). Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO guideline. <https://asco.org>. Published December 15, 2022.
4. American Society of Clinical Oncology (ASCO). Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. <https://asco.org>. Published February 17, 2022.
5. College of American Pathologists (CAP). Molecular biomarker testing for the diagnosis of diffuse gliomas: guideline from the College of American Pathologists in collaboration with the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology. <https://cap.org>. Published May 2022.
6. National Comprehensive Cancer Network (NCCN). NCCN Biomarkers Compendium: FGFR3, IDH1, IDH2, MGMT, PIK3CA, TERT. <https://nccn.org>. Updated 2025.

7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Biliary tract cancers. <https://nccn.org>. Updated March 20, 2025.
8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bladder cancer. <https://nccn.org>. Updated January 17, 2025.
9. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer. <https://nccn.org>. Updated March 18, 2025.
10. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Central nervous system cancers. <https://nccn.org>. Updated January 21, 2025.
11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Head and neck cancers. <https://nccn.org>. Updated January 17, 2025.
12. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Melanoma: cutaneous. <https://nccn.org>. Updated January 28, 2025.
13. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Uterine neoplasms. <https://nccn.org>. Updated March 7, 2025.
14. Society for Immunotherapy of Cancer (SITC). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. <https://sitcancer.org>. Published August 13, 2021.
15. UpToDate, Inc. Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors. <https://uptodate.com>. Updated January 2025.
16. UpToDate, Inc. Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas. <https://uptodate.com>. Updated January 2025.
17. UpToDate, Inc. Initial treatment and prognosis of IDH-wildtype glioblastoma in adults. <https://uptodate.com>. Updated January 2025.
18. UpToDate, Inc. Malignant salivary gland tumors: treatment of recurrent and metastatic disease. <https://uptodate.com>. Updated January 2025.
19. UpToDate, Inc. Management of glioblastoma in older adults. <https://uptodate.com>. Updated January 21, 2025.
20. UpToDate, Inc. Melanoma: clinical features and diagnosis. <https://uptodate.com>. Updated January 2025.
21. UpToDate, Inc. Overview of the approach to metastatic breast cancer. <https://uptodate.com>. Updated January 2025.

22. UpToDate, Inc. Overview of the management of advanced cutaneous melanoma. <https://uptodate.com>. Updated January 2025.
23. UpToDate, Inc. Principles of cancer immunotherapy. <https://uptodate.com>. Updated January 2025.
24. UpToDate, Inc. Prognostic and predictive factors in metastatic breast cancer. <https://uptodate.com>. Updated January 2025.
25. UpToDate, Inc. Systemic therapy for advanced unresectable and metastatic cholangiocarcinoma. <https://uptodate.com>. Updated January 2025.
26. UpToDate, Inc. Systemic treatment of metastatic melanoma with BRAF and other molecular alterations. <https://uptodate.com>. Updated January 2025.
27. UpToDate, Inc. Treatment of advanced unresectable and metastatic gallbladder cancer. <https://uptodate.com>. Updated January 2025.
28. UpToDate, Inc. Treatment for hormone receptor-positive, HER2-negative advanced breast cancer. <https://uptodate.com>. Updated January 31, 2025.
29. UpToDate, Inc. Treatment of metastatic breast cancer in older women. <https://uptodate.com>. Updated August 2024.
30. UpToDate, Inc. Treatment of metastatic urothelial cancer of the bladder and urinary tract. <https://uptodate.com>. Updated January 7, 2025.
31. US Food & Drug Administration (FDA). Full prescribing information: Balversa (erdafitinib). <https://fda.gov>. Published 2019. Updated October 2024.
32. US Food & Drug Administration (FDA). Full prescribing information: Faslodex (fulvestrant). <https://fda.gov>. Published 2002. Updated January 2021.
33. US Food & Drug Administration (FDA). Full prescribing information: Ibrance- palbociclib). <https://fda.gov>. Published 2015. Updated December 2024.
34. US Food & Drug Administration (FDA). Full prescribing information: Itovebi (inavolisib)). <https://fda.gov>. Published 2024. Updated January 2025.
35. US Food & Drug Administration (FDA). Full prescribing information: Piqray (alpelisib). <https://fda.gov>. Published 2019. Updated January 2024.
36. US Food & Drug Administration (FDA). In vitro companion diagnostic devices. <https://fda.gov>. Published August 6, 2014.

37. US Food & Drug Administration (FDA). Laboratory developed tests. <https://fda.gov>. Updated October 30, 2024.
 38. US Food & Drug Administration (FDA). List of cleared or approved companion diagnostic devices (in vitro and imaging tools). <https://fda.gov>. Updated 2025.
 39. US Food & Drug Administration (FDA). Premarket approval. theascreen PIK3CA RGQ PCR Kit. <https://fda.gov>. Published May 24, 2019.
-

Tumor Markers

Description

A **tumor marker** is a protein, antibody, antigen or hormone in the body that may indicate the presence of cancer. Generally, these markers are specific to certain types of cancer and can be detected in blood, body fluids (eg, cerebral spinal fluid [CSF]), stool, tissue and urine samples. The body may produce the marker in response to cancer or the tumor itself may produce the marker. The detection of tumor markers may be used to determine a diagnosis or as an indicator of disease (cancer) progression. It can also be used to document clinical response to treatment. Examples of tumor markers include, but are not limited to:

- **Des-gamma-carboxy prothrombin (DCP)** (also referred to as protein induced by vitamin K absence-II) has been proposed diagnosis and monitoring of hepatocellular carcinoma (liver cancer) as a way to distinguish malignant from benign liver conditions.
- **Human epididymis protein 4 (HE4) (eg, Elecsys HE4 Assay)** has been proposed to aid in the detection and monitoring of ovarian cancer.
- **IsoPSA** is a prostate cancer biomarker test that assesses changes in prostate specific antigen (PSA) proteins to purportedly aid in the detection of high-grade prostate cancer.

Coverage Determination

Human Epididymis Protein 4 (HE4)

Humana members may be eligible under the Plan for **human epididymis protein 4 (HE4) testing (86305)** for the following indications:

- Newly diagnosed ovarian, fallopian tube or primary peritoneal cancer; **OR**
- Suspicious palpable pelvic mass on abdomen/pelvis examination; **AND/OR**
- Ascites, abdominal distention; **AND/OR**

- Symptoms without source of malignancy (eg, bloating, difficulty eating or feeling full quickly, pelvis/abdomen pain, urinary symptoms [frequency or urgency])

IsoPSA Test

Humana members may be eligible under the Plan for **IsoPSA test (0359U)** when the following criteria are met:

- Individual 50 years of age or older; **AND**
- Prostate specific antigen (PSA) greater than 4 and less than or equal to 25 ng/mL

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for **des-gamma-carboxy prothrombin (DCP) (83951) testing**.

A review of the current medical literature shows that the **evidence is insufficient** to determine that this service is standard medical treatment. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of this service in clinical management.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
83951	Oncoprotein; des-gamma-carboxy-prothrombin (DCP)	
86305	Human epididymis protein 4 (HE4)	
0359U	Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		

HCPCS Code(s)	Description	Comments
No code(s) identified		

References

1. American Association for the Study of Liver Diseases (AASLD). AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. <https://aasld.org>. Published December 2023.
2. American Society of Clinical Oncology (ASCO). Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update. <https://asco.org>. Published August 4, 2016. Updated February 6, 2025.
3. ClinicalKey. Clinical Overview. Hepatocellular carcinoma. <https://clinicalkey.com>. Updated January 21, 2025.
4. ECRI Institute. ECRI Genetic Test Assessment. IsoPSA Test (Cleveland Diagnostics, Inc.) for assessing risk of aggressive prostate cancer. <https://home.ecri.org>. Published October 2021.
5. Hayes, Inc. Medical Technology Directory. Architect HE4 assay for ovarian cancer detection. <https://evidence.hayesinc.com>. Published December 30, 2012. Updated December 5, 2016.
6. Hayes, Inc. Precision Medicine Research Brief. IsoPSA Test (Cleveland Diagnostics Inc.). <https://evidence.hayesinc.com>. Published December 19, 2023.
7. Klein EA, Partin A, Lotan Y, et al. Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study. *Urol Oncol*. 2022;40(9):408.e9-408.e18.
8. National Comprehensive Cancer Network (NCCN). NCCN Biomarkers Compendium. HE4 expression, IsoPSA. <https://nccn.org>. Updated 2025.
9. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Hepatocellular carcinoma. <https://nccn.org>. Updated March 20, 2025.
10. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. <https://nccn.org>. Updated March 5, 2025.
11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate cancer early detection. <https://nccn.org>. Updated March 11, 2025.

12. UpToDate, Inc. Adnexal mass: evaluation and management in pregnancy. <https://uptodate.com>. Updated March 14, 2025.
13. UpToDate, Inc. Adnexal mass: role of serum biomarkers in diagnosing epithelial carcinoma of the ovary, fallopian tube, or peritoneum. <https://uptodate.com>. Updated March 2025.
14. UpToDate, Inc. Approach to the patient with an adnexal mass. <https://uptodate.com>. Updated March 2025.
15. UpToDate, Inc. Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer. <https://uptodate.com>. Updated March 2025.
16. UpToDate, Inc. Clinical features and diagnosis of hepatocellular carcinoma. <https://uptodate.com>. Updated March 5, 2025.
17. UpToDate, Inc. Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: clinical features and diagnosis. <https://uptodate.com>. Updated March 2025.
18. UpToDate, Inc. Screening for ovarian cancer. <https://uptodate.com>. Updated March 2025.
19. UpToDate, Inc. Surveillance for hepatocellular carcinoma in adults. <https://uptodate.com>. Updated March 3, 2025.
20. UpToDate, Inc. Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time). <https://uptodate.com>. Updated March 2025.
21. US Food & Drug Administration (FDA). 510k summary: Architect HE4. <https://fda.gov>. Published March 18, 2010.
22. US Food & Drug Administration (FDA). 510k summary: Wako LBA DCP Test System. <https://fda.gov>. Published January 31, 2007.

Change Summary

08/05/2025 New Policy.